1.Hepatocellular carcinoma with lymphoid stroma: report of two cases.
Hye Jeong CHOI ; Joon Hyuck CHOI
The Korean Journal of Hepatology 2008;14(3):394-398
We report two cases of hepatocellular carcinoma with prominent lymphocytic infiltration, which has been described as a subtype of hepatocellular carcinoma with good prognosis. One case showed lymphoid follicles and dense lymphocytic infiltrates within the tumor and its periphery, and the other case showed marked lymphocytic infiltration in the cancerous tissue. Piecemeal necrosis of cancer cells and atypical reactive changes were evident. The two cases were seronegative for hepatitis B surface antigen, antibody to hepatitis C virus, and Epstein-Barr virus DNA. One of the cases showed Clonorchis infestation. The prognostic significance of lymphocytic stroma in hepatocellular carcinoma requires further investigation.
Animals
;
Carcinoma, Hepatocellular/*diagnosis/pathology
;
Clonorchiasis/diagnosis/parasitology
;
Clonorchis sinensis
;
Diagnosis, Differential
;
Female
;
Humans
;
Liver Neoplasms/*diagnosis/pathology
;
Lymphocytes, Tumor-Infiltrating/*pathology
;
Male
;
Middle Aged
;
Tomography, X-Ray Computed
2.A Diffusion-based Model Theory of Passive-Targeted Drug Delivery in Solid Tumors.
Joon Hyuck CHOI ; Nam Lyong KANG ; Sang Don CHOI
Korean Journal of Medical Physics 2007;18(3):161-166
A model theory of passive-targeted drug delivery in sphere-shaped solid tumors is introduced on the basis of Fick's law of diffusion, with appropriate boundary and initial conditions. For a uniform initial concentration inside the tumor, the concentration is obtained as a function of time and radial position. The concentration is shown to approach the equilibrium distribution as the time elapses, as is expected by the Gedanken Experiment. The time-evolution rate is found to be determined by the diffusion coefficient of the drug in the tissue, the size of the tumor, the volume of the drug-injected region, and the concentration gradient at the boundary.
Diffusion
;
Jurisprudence
3.The present and the future of therapeutic endoscopy in the pancreatic disease.
Ho Gak KIM ; Jimin HAN ; Joon Hyuck CHOI
Korean Journal of Medicine 2006;70(5):478-494
No abstract available.
Endoscopy*
;
Pancreatic Diseases*
4.A Case of Ocular Deviation after Excinier Laser Photorefractive Keratectomy.
Yoon Heui KIM ; Yong Joon CHOI ; Sang Hoon RAH ; Jong Hyuck LEE
Journal of the Korean Ophthalmological Society 1998;39(6):1291-1293
Patients undergoing monocular excimer laser photorefractive keratectomy (PRK) for myopic correction can develop strabismus secondary to decompensated heterophorias. We experienced a case of ocular esodeviation and diplopia that developed 8 nionths after monocular excimer laser phtorefractive keratectomy. So, we report this case with 8 review of the literature.
Diplopia
;
Esotropia
;
Humans
;
Lasers, Excimer
;
Photorefractive Keratectomy*
;
Strabismus
5.A clinicopathologic study of lupus nephritis in children.
Hye Ok ROH ; Ki Soo PAI ; Kee Hyuck KIM ; Jae Seung LEE ; Pyung Kil KIM ; Hyeon Joo JEONG ; In Joon CHOI
Korean Journal of Nephrology 1993;12(3):334-342
No abstract available.
Child*
;
Humans
;
Lupus Nephritis*
6.Nonimmune Hydrops Fetalis in One Identical Twin: A Case of Spontaneous Reversal in Utero.
Sang Joon CHOI ; Young Ho KIM ; Chang Hoon SONG ; Hyuck JUNG
Korean Journal of Obstetrics and Gynecology 1997;40(9):2048-2054
Nonimmune hydrops fetals is defined as generalized edema of the fetal soft tissue in utero and may be associated with effusion in the serous cavities without hematologic evidence of isoimmunization. The most common demonstrable causes are cardiac anomalies, followed by chromosomal disorders, congenital malformations, alpha-thalassemia, and the twin-twin transfu-sion syndrome. We have experienced a case of nonimmune hydrops fetalis in identical twin which caused by congenital mitral valve insufficiency and disappeared spontaneously at 35 wks. Now we report a case of nonimmune hydrops fetalis that slowly and spontaneously imp-roved without interventions with a brief review of related literatures.
alpha-Thalassemia
;
Chromosome Disorders
;
Edema
;
Humans
;
Hydrops Fetalis*
;
Mitral Valve Insufficiency
;
Twins, Monozygotic*
7.Expression of c-erbB-2 and Cyclooxygenase-2 in Pancreatic Ductal Adenocarcinoma.
Hye Jeong CHOI ; Hong Jin KIM ; Sung Soo YUN ; Joon Hyuck CHOI
Korean Journal of Pathology 2007;41(3):171-175
Background : Carcinoma of the pancreas is a fatal malignant disease with limited therapeutic options. Cyclooxygenase-2 (COX-2) and c-erbB-2 are known to be involved in the carcinogenesis, differentiation and invasiveness of various neoplasms. We studied the immunohistochemical expressions of c-erbB-2 and COX-2 and the correlation between these expressions and the clinicopathologic parameters and the relation between the expressions. Methods : Immunohistochemical staining for c-erbB-2 and COX-2 were performed on the paraffin embedded sections of 36 cases of surgically resected ductal adenocarcinoma of the pancreas and 10 cases of non-neoplastic pancreas tissue. Results : The non-neoplastic control group showed a c-erbB-2 expression in the acini (8/10) and ducts (2/10), and a COX-2 expression in the acini (6/10) and ducts (3/10). The overexpression of c-erbB-2 was observed in 58% (21/36) of the carcinoma specimens. No significant correlation was found between c-erbB-2 and age, gender, tumor size, gross type, histologic grade, vascular invasion, perineural invasion, lymph node metastasis, and the TNM stage. The overexpression of COX-2 was observed in 41.7% (15/36) of the carcinoma specimens. The COX-2 expression was significantly high in the lymph node metastasis group (p<0.05), but it was not correlated with the other clinicopathologic parameters. Also there was no significant correlation between the c-erbB-2 and COX-2 expressions. Conclusions : In pancreatic ductal adenocarcinomas, c-erbB-2 and COX-2 were frequently overexpressed, and COX-2 overexpression was correlated with lymph node metastasis.
Adenocarcinoma*
;
Carcinogenesis
;
Cyclooxygenase 2*
;
Immunohistochemistry
;
Lymph Nodes
;
Neoplasm Metastasis
;
Pancreas
;
Pancreatic Ducts*
;
Paraffin
;
Receptor, erbB-2
8.Central Retinal Vein Occlusion During Embolization for Carotid Cavernous Sinus Fistula.
Seok Joon LEE ; Jae Hun HYUN ; Jong Hyuck LEE ; Joong Kon CHOI
Journal of the Korean Ophthalmological Society 1998;39(12):3018-3023
Most trauma induced fistulas are direct communications between the intracavernous carotid artery and the cavernous sinus. Theses abnormal communications are characterized by high pressure, high blood flow and a clinically obvious constellation of symptoms and signs. We here in report a patient with traumatic carotid cavernous sinus fistula(CCSF). who developed central retinal vein occlusion(CRVO) during detachable balloon embolization. The mechanism of CRVO occurring during detachable balloon embolization. The mechanism of CRVO occurring during detachable ballon embolization for CCSF was discussed. We report this case with the review of previous reports.
Balloon Occlusion
;
Carotid Arteries
;
Carotid-Cavernous Sinus Fistula*
;
Cavernous Sinus
;
Fistula
;
Humans
;
Retinal Vein*
9.A Case of Type 1 Ushers Syndrome with Bilateral Cataract.
Seok Joon LEE ; Jong Hyuck LEE ; Yong Jun CHOI ; Jong Wook KIM
Journal of the Korean Ophthalmological Society 1998;39(4):784-789
Ushers syndrome is an autosomal recessively inherited entity which is characterized by a retinitis pigmentosa and congenital sensorineural hearing loss. This syndrome represents different clinical features according to its subtypes. We experienced one case of type 1 Ushers syndrome, who had congenital hearing loss, visual field loss, visual loss of early childhood onset. We performed bilateral cataract extraction. Fundus examination after operation showed characteristic findings of retinitis pigmentosa. ERG was non-recordable ERG. Her audiogram confirmed the bilateral sensorineural hearing loss.
Cataract Extraction
;
Cataract*
;
Hearing Loss
;
Hearing Loss, Sensorineural
;
Retinitis Pigmentosa
;
Usher Syndromes*
;
Visual Fields
10.Efficacy and Safety of Atorvastatin in Patients with Hypercholesterolemia.
Jong Hoon KOH ; Joon Han SHIN ; Han Soo KIM ; Seung Jea TAHK ; Byung Il CHOI ; Dongsoo KIM ; Hyuck Moon KWON ; Hyun Seung KIM
Korean Circulation Journal 1999;29(9):928-936
BACKGROUND: Previous studies indicated that a recently approved synthetic HMG-CoA reductase inhibitor, atorvastatin, reduces LDL cholesterol and triglyceride. To assess the efficacy on the level of serum LDL cholesterol and other lipoprotein fractions and its safety, we investigated 59 patients for lipid and side effect profile. METHOD: In patients with hypercholesterolemia, who showed 12-hours fasting serum LDL cholesterol>145 mg/dl and <250 mg/dl and triglyceride levels<400 mg/dl were enrolled to diet therapy for 4 weeks. After 4 weeks of diet therapy, serum lipid profile were reevaluated and patients with LDL cholesterol > or =130 mg/dl were assigned to receive 10 mg dose of atorvastatin once daily for 4weeks. After 4 weeks of drug therapy, serum lipid profile were rechecked, if showed LDL cholesterol level> or =130 mg/dl, assigned to receive 20 mg dose of atorvastatin once daily until 8 weeks. RESULTS: Of the 59 patients were assigned to receive atorvastatin therapy, 52 patients completed the study. Among lipid profiles, total cholesterol, triglyceride, LDL-cholesterol and apolipoprotein B levels showed significant reduction with mean reduction rate of 28%, 13%, 38%, 32% respectively after 4 weeks and 31%, 13%, 41% and 34% respectively after 8 weeks. HDL-Cholesterol and lipoprotein (a) level did not show significant change after 8 weeks of therapy. Nine patients had mild adverse events, such as elevated ALT, epigastric pain, insomnia, thumb pain. postural hypotension, palpitation and constipation. Only three patients of fifty-nine withdrew from the study due to adverse events related to drug treatment. CONCLUSION: The atorvastatin was highly effective and generally well tolerated with an acceptable safety profile in patients with primary hypercholestelemia.
Apolipoproteins
;
Cholesterol
;
Cholesterol, LDL
;
Constipation
;
Diet Therapy
;
Drug Therapy
;
Fasting
;
Humans
;
Hypercholesterolemia*
;
Hypotension, Orthostatic
;
Lipoprotein(a)
;
Lipoproteins
;
Oxidoreductases
;
Sleep Initiation and Maintenance Disorders
;
Thumb
;
Triglycerides
;
Atorvastatin Calcium